Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larissa A Korde

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
The Oncologist|May 20, 2015
Male Breast Cancer: A Study in Small StepsLarissa A Korde
Oncology (Williston Park, N.Y.)|June 24, 2010
Are bisphosphonates ready for the adjuvant setting?Larissa A Korde, Julie R Gralow
Journal of the National Cancer Institute|March 28, 2023
Response to SongLarissa A Korde, Ana F Best
JAMA Oncology|August 21, 2019
Hereditary Cancer Evaluation in 2019-a Rapidly Evolving LandscapeRachel L Yung, Larissa A Korde
Primary Care|July 21, 2009
Cancer risk assessment for the primary care physicianLarissa A Korde, Shahinaz M Gadalla
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
Can we predict who's at risk for developing bone metastases in breast cancer?Larissa A Korde, Julie R Gralow
Postgraduate Medicine|October 30, 2004
Assessing breast cancer risk: genetic factors are not the whole storyLarissa A Korde, Kathleen A Calzone, JoAnne Zujewski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2023
Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic DiseaseBoris Freidlin, Larissa A Korde, Edward L Korn
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2021
A Case-Based Approach to Understanding Complex Genetic Information in an Evolving LandscapeCourtney D DiNardo, Larissa A Korde, Matthew B Yurgelun
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2022
Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation UpdateLarissa A Korde, Mark R Somerfield, Dawn L Hershman, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
The Oncologist|May 20, 2015
Male Breast Cancer: A Study in Small StepsLarissa A Korde
Oncology (Williston Park, N.Y.)|June 24, 2010
Are bisphosphonates ready for the adjuvant setting?Larissa A Korde, Julie R Gralow
Journal of the National Cancer Institute|March 28, 2023
Response to SongLarissa A Korde, Ana F Best
JAMA Oncology|August 21, 2019
Hereditary Cancer Evaluation in 2019-a Rapidly Evolving LandscapeRachel L Yung, Larissa A Korde
Primary Care|July 21, 2009
Cancer risk assessment for the primary care physicianLarissa A Korde, Shahinaz M Gadalla
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
Can we predict who's at risk for developing bone metastases in breast cancer?Larissa A Korde, Julie R Gralow
Postgraduate Medicine|October 30, 2004
Assessing breast cancer risk: genetic factors are not the whole storyLarissa A Korde, Kathleen A Calzone, JoAnne Zujewski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2023
Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic DiseaseBoris Freidlin, Larissa A Korde, Edward L Korn
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2021
A Case-Based Approach to Understanding Complex Genetic Information in an Evolving LandscapeCourtney D DiNardo, Larissa A Korde, Matthew B Yurgelun
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2022
Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation UpdateLarissa A Korde, Mark R Somerfield, Dawn L Hershman, et al.
Pageof 7